Finerenone Side Effects
Medically reviewed by Drugs.com. Last updated on May 28, 2024.
Applies to finerenone: oral tablet.
Serious side effects of finerenone
Along with its needed effects, finerenone may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking finerenone:
More common side effects
Less common side effects
- blurred vision
- coma
- decreased urine output
- dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
- fast heartbeat
- headache
- increase thirst
- muscle pain or cramps
- seizures
- sweating
- swelling of the face, ankles, or hands
- unusual tiredness or weakness
For healthcare professionals
Applies to finerenone: oral tablet.
General adverse events
The most frequently reported adverse reaction was hyperkalemia.[Ref]
Cardiovascular
- Common (1% to 10%): Hypotension (includes blood pressure decreased, diastolic blood pressure decreased, diastolic hypotension, hypotension)
- Frequency not reported: Systolic blood pressured decreased, diastolic blood pressure decreased[Ref]
In patients treated with this drug, the mean systolic and diastolic blood pressure decreased by 2 to 4 mmHg and 1 to 2 mmHg, respectively, at month 1 and remained stable thereafter. Most hypotension events were mild or moderate and resolved; events associated with hypotension (e.g., dizziness, syncope, fall) were not more frequent in patients treated with this drug compared to placebo.[Ref]
Dermatologic
Hematologic
- Common (1% to 10%): Anemia
- Uncommon (0.1% to 1%): Hemoglobin decreased
- Frequency not reported: Hematocrit decreased[Ref]
Metabolic
- Very common (10% or more): Serum potassium increased (up to 21.7%), hyperkalemia (includes blood potassium increased, hyperkalemia; up to 18.3%)
- Common (1% to 10%): Hyponatremia (includes blood sodium decreased, hyponatremia)[Ref]
In a study, hyperkalemia events were reported in 18.3% of patients treated with this drug; most hyperkalemia events were mild to moderate in patients treated with this drug. Serious hyperkalemia events were report more often for this drug than placebo; serum potassium levels greater than 5.5 mmol/L and greater than 6 mmol/L were reported in 21.7% and 4.5% of patients treated with this drug and in 9.8% and 1.4% of those treated with placebo, respectively.
An increase from baseline in mean serum potassium in the first month of therapy was about 0.2 mmol/L in patients treated with this drug.[Ref]
Nervous system
- Frequency not reported: Dizziness, syncope[Ref]
Other
- Frequency not reported: Fall[Ref]
Renal
- Common (1% to 10%): Estimated glomerular filtration rate (eGFR) decreased/GFR decreased[Ref]
This drug caused an initial small decrease in eGFR (mean 2 mL/min/1.73 m2); it occurred within the first 4 weeks of therapy and then stabilized. In a study including patients with chronic kidney disease associated with type 2 diabetes, this decrease was reversible after therapy was stopped.[Ref]
References
1. (2022) "Product Information. Kerendia (finerenone)." Bayer Plc
2. (2021) "Product Information. Kerendia (finerenone)." Bayer Pharmaceutical Inc
3. (2021) "Product Information. Kerendia (finerenone)." Bayer Australia Ltd, 1.0
More about finerenone
- Check interactions
- Compare alternatives
- Reviews (3)
- Dosage information
- During pregnancy
- Drug class: aldosterone receptor antagonists
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Finerenone side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.